Ixazomib

Multiple Myeloma Treatment

Ixazomib is used to treat multiple myeloma, which is a cancer that begins in the plasma cells of the bone marrow. When these cells become cancerous, they grow out of control and can damage the bones, immune system, and kidneys.

Combination Therapy

This medication is not used by itself. It is prescribed as part of a specific treatment regimen that includes two other drugs:

• Lenalidomide: An immunomodulatory medication.
• Dexamethasone: A corticosteroid medication.

Together, these three medications work to slow the growth of cancer cells and help the body manage the disease.

When It Is Prescribed

Ixazomib is typically used for patients who have already undergone at least one previous round of treatment for multiple myeloma. It is often used when the cancer has relapsed, meaning it returned after a period of improvement, or is refractory, meaning it did not respond to the initial treatment.

Mechanism of Action

Ixazomib belongs to a class of medications called proteasome inhibitors. It works by targeting and blocking the activity of proteasomes, which are enzyme complexes found within cells.

Proteasomes function as a waste disposal system for cells, breaking down and recycling proteins that are damaged or no longer needed. Cancer cells, particularly multiple myeloma cells, produce proteins at a high rate and depend on proteasomes to keep the cell functioning properly.

When ixazomib blocks these proteasomes, the following occurs:

• Protein Buildup: Unwanted proteins begin to accumulate inside the cancer cell because they cannot be broken down.
• Cellular Stress: The buildup of these proteins creates a toxic environment and causes significant stress to the cell structure.
• Cell Death: This internal stress eventually triggers the cancer cell to stop dividing and undergo a process of programmed cell death.

Because cancer cells are often more dependent on proteasome activity than healthy cells, they are more sensitive to the effects of this medication. This allows the drug to help slow or stop the progression of the cancer while minimizing the impact on normal cells.

Common Side Effects

The most frequently reported side effects of ixazomib include:

• Nausea and vomiting
• Diarrhea or constipation
• Swelling of the hands, ankles, or feet
• Skin rash
• Back pain
• Fatigue or weakness
• Numbness, tingling, or burning pain in the hands or feet (peripheral neuropathy)

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious symptoms:

• Signs of low platelet or white blood cell counts, such as unusual bruising, bleeding, or signs of infection like fever
• Severe or persistent digestive issues, including intense diarrhea or vomiting
• Liver problems, such as yellowing of the skin or eyes, dark urine, or upper stomach pain
• Severe skin reactions, including rashes that blister or peel
• Vision changes, such as blurred vision or eye dryness
• Symptoms of shingles (herpes zoster), such as a painful, blistering skin rash
• New or worsening shortness of breath or cough

Thrombocytopenia

Low platelet counts (thrombocytopenia) are common with ixazomib. This can increase the risk of bleeding. Platelet counts are typically monitored at least monthly, and more frequently (weekly) during the first two cycles of treatment.

Gastrointestinal Toxicities

Diarrhea, constipation, nausea, and vomiting are frequently reported. In some cases, these symptoms may be severe and require medical management with fluids or medications.

Peripheral Neuropathy

Patients may experience numbness, tingling, or burning sensations in the hands or feet. Dose adjustments may be necessary if these symptoms become severe.

Peripheral Edema

Swelling of the extremities (arms and legs) can occur. Monitoring for fluid retention is recommended.

Skin Reactions

Rashes are common. However, serious skin reactions, including Stevens-Johnson syndrome, have been reported. Treatment should be stopped if a severe rash develops.

Hepatotoxicity

Drug-induced liver injury has occurred. Liver enzymes and bilirubin levels should be monitored regularly during treatment.

Embryo-Fetal Toxicity

Ixazomib can cause harm to a developing fetus. Effective contraception is recommended for both males and females during treatment and for a period after the final dose.

Thrombotic Microangiopathy

Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura (TTP), have been reported. This is a serious condition involving blood clots in small vessels.

Pregnancy

Ixazomib may cause fetal harm when administered to a pregnant woman. Animal studies have indicated that the drug can cause structural abnormalities and fetal death. Because of these risks, healthcare providers typically perform a pregnancy test before starting treatment to ensure a patient is not pregnant.

Patients of reproductive potential should use effective contraception according to the following guidelines:

• Females: Use effective birth control during treatment and for at least 90 days after the final dose.
• Males: Use effective birth control (such as condoms) during treatment and for at least 90 days after the final dose if their partner is pregnant or could become pregnant.

If a patient becomes pregnant while taking this medication, they should contact their healthcare provider immediately to discuss the potential risks to the fetus.

Breastfeeding

It is not known whether ixazomib passes into human breast milk. Because many drugs are excreted in human milk and there is a potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment. Patients should avoid breastfeeding while taking ixazomib and for at least 90 days after the last dose.

Available Forms

Ixazomib is supplied as a capsule for oral administration. The capsules are color-coded to help distinguish between the different strengths available.

The medication is typically provided in blister packaging. It is important to keep the capsules in their original container until the time of use and to avoid breaking or opening the capsules.

FDA Approval and Indications

Ixazomib was approved by the U.S. Food and Drug Administration (FDA) in November 2015. It is indicated for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Safety and Monitoring

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) programs required for ixazomib. However, the FDA monitors the safety of the drug through the FDA Adverse Event Reporting System (FAERS). In 2018, the FDA identified potential signals of serious skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, which led to updates in the product labeling to include these risks.

Healthcare providers are advised to monitor patients for signs of severe skin reactions, liver toxicity, and low platelet counts while they are taking this medication.

Insurance and Prior Authorization

Ixazomib is a specialty medication used for the treatment of multiple myeloma. Most private insurance plans and Medicare Part D provide coverage for this drug, but out-of-pocket costs can vary. Insurance companies often require prior authorization, a process where the healthcare provider must justify the medical necessity of the drug before the insurer agrees to cover the cost.

Specialty Pharmacy Requirements

Because ixazomib requires special handling and monitoring, it is typically dispensed through specialty pharmacies rather than standard retail pharmacies. These specialty pharmacies often coordinate with insurance providers and may offer services to help patients manage the high cost of the medication.

Financial Assistance Programs

For patients who face high out-of-pocket expenses or lack insurance coverage, financial assistance may be available. Many manufacturers offer patient assistance programs or copay cards to reduce the cost for eligible individuals. Additionally, independent non-profit foundations may provide grants to help cover the costs of cancer treatments for those who meet specific financial criteria.

Generic Availability

Ixazomib is currently available as a brand-name medication. Generic versions are not yet widely available, which generally results in a higher cost compared to medications that have generic alternatives.